

Abstract 1279

Long Term Overall Survival Follow-up of Toripalimab versus Placebo in Combination with Gemcitabine and Cisplatin as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Type: Abstract

Topic: Head and neck cancer, excluding thyroid

Authors: H.-Q. Mai¹, Q.Y. Chen¹, D. Chen², C. Hu³, K. Yang⁴, J. Wen⁵, J. Li⁶, Y. Shi⁷, F. Jin⁸, R. Xu⁹, J. Pan¹⁰, S. Qu¹¹, P. Li¹², C. Hu¹³, Y.C. Liu¹⁴, Y. Jiang¹⁵, X. He¹⁶, H.M. Wang¹⁷, D.W.-T. Lim¹⁸, R.-H. Xu¹⁹; ¹Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, China, ²Radiation Oncology, Affiliated Cancer Hospital and Insitutue of Guangzhou Medical University, Guangzhou, China, ³Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, ⁴Oncology Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology/ Cancer Center Union Hospital, Wuhan, China, ⁵Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China, ⁶Oncology, Jiangxi Provincial Cancer Hospital, Nanchang, China, ⁷Department II of Head and Neck Radiotherapy, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, ⁸Oncology, Guizhou Cancer Hospital of Guizhou Medical University, Guiyang, China, ⁹Oncology, Shenzhen People's Hospital, Shenzhen, China, ¹⁰Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, China, ¹¹Oncology, The Peoples Hospital of Guangxi Zhuang Autonomous Region, Nanning, China, ¹²Oncology, West China Hospital of Sichuan University, Chengdu, China, ¹³Oncology, The Second Xiangya Hospital of Central South University, Changsha, China, ¹⁴Radiation Oncology, Taichung Veterans General Hospital, Taichung City, Taiwan, ¹⁵Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China, ¹⁶Oncology, Jiangsu Cancer Hospital, Nanjing, China, ¹⁷Oncology, Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan, ¹⁸Medical Oncology department, NCCS - National Cancer Centre Singapore, Singapore, Singapore, ¹⁹Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

Background

Toripalimab plus Gemcitabine-Cisplatin (GP) as a first-line treatment for recurrent or metastatic (RM) NPC has been approved in more than forty countries based on the results of the JUPITER-02 study (NCT03581786), in which significant overall survival benefits were demonstrated with the addition of toripalimab to chemotherapy. Here we present the long-term overall survival results, as well as a sensitivity analysis evaluating the impact of post-progression immunotherapy on survival.

Methods

RM-NPC patients were randomized to receive toripalimab 240 mg (n=146) or placebo (n=143) in combination with GP once every 3 weeks (Q3W) for up to 6 cycles, followed by toripalimab or placebo Q3W until disease progression, intolerable toxicity, or maximum of 2-year of treatment. Stratification factors were ECOG performance (0 vs. 1) and disease status (recurrent vs. primary metastatic). The primary endpoint was PFS by an independent review committee and OS was a key secondary endpoint.

Results

As of June 24, 2025, 68 months after the last enrollment, 156 deaths have occurred. The median OS was 64.8 months in the toripalimab arm and 33.7 months in the placebo arm. The hazard ratio (HR) was 0.62 (95% CI: 0.45-0.85), nominal p=0.0027. For patients who experienced disease progression, 43% received later-line immunotherapy. Sensitivity analyses were conducted to further assess the impact of post-progression immunotherapy on survival. Among the intent-to-treat population, after adjusting for post-progression anti-PD-

(L)1 therapy, the HR was 0.52 (95% CI: 0.38-0.72), median OS 61.0 vs. 25.1 months in the toripalimab and placebo arms respectively. The improved HR of the sensitivity analysis over the unadjusted analysis suggests that post-progression immunotherapy had more favorable effect on survival in the placebo arm.

Conclusions

Toripalimab plus GP chemotherapy demonstrated significant survival benefits over GP alone as a first-line treatment for RM-NPC. The median OS reached 64.8 months in the toripalimab arm, with a 31-month improvement over GP alone. Toripalimab plus GP chemotherapy represents the new standard care for patients with RM-NPC.

Clinical trial identification

NCT03581786

Editorial acknowledgement

Print